Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Employee Rating

0More
TypePublic
HQMilpitas, US
Founded2007
Size (employees)49 (est)+69%
Websiteprotagonist-inc.com
Protagonist Therapeutics was founded in 2007 and is headquartered in Milpitas, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Protagonist Therapeutics

Dinesh Patel

Dinesh Patel

President & CEO
David Y. Liu

David Y. Liu

Chief Scientific Officer
Mark Smythe

Mark Smythe

Vice President of Technology & Alliances
Show more

Protagonist Therapeutics Office Locations

Protagonist Therapeutics has an office in Milpitas
Milpitas, US (HQ)
100 521 Cottonwood Dr
Show all (1)
Report incorrect company information

Protagonist Therapeutics Financials and Metrics

Protagonist Therapeutics Revenue

USD

Net income (Q2, 2018)

(8.7m)

EBIT (Q2, 2018)

(9.2m)

Market capitalization (14-Dec-2018)

166.6m

Closing stock price (14-Dec-2018)

6.9

Cash (31-Dec-2017)

106.0m
Protagonist Therapeutics's current market capitalization is $166.6 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

7.0m11.8m

R&D expense

25.7m46.2m

Operating expense total

32.7m58.0m

EBIT

(32.7m)(37.9m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.4m1.6m3.0m3.1m2.6m3.6m3.2m

R&D expense

5.7m5.6m11.3m12.0m11.2m15.4m17.7m

Operating expense total

7.1m7.1m14.3m15.1m13.8m19.0m20.9m

EBIT

(7.1m)(7.1m)(14.3m)(15.1m)(5.0m)(8.2m)(9.2m)
Annual
USDFY, 2016FY, 2017

Cash

21.1m106.0m

Inventories

3.4m

Current Assets

83.2m150.9m

PP&E

562.0k879.0k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

13.8m96.0m9.5m10.4m50.4m

Current Assets

22.4m102.2m67.5m69.1m97.7m

PP&E

599.0k564.0k641.0k903.0k945.0k

Total Assets

24.5m102.8m82.7m70.5m110.4m
Annual
USDFY, 2016FY, 2017

Net Income

(37.2m)(37.0m)

Depreciation and Amortization

317.0k406.0k

Inventories

(1.8m)

Accounts Payable

(115.0k)91.0k
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(18.8m)(25.9m)(14.1m)(29.1m)(33.9m)(7.7m)(16.3m)

Depreciation and Amortization

159.0k242.0k88.0k181.0k289.0k78.0k248.0k

Accounts Payable

85.0k157.0k(151.0k)1.4m1.1m21.0k1.0m

Cash From Operating Activities

(13.3m)(20.3m)(10.4m)(22.7m)18.0m(15.1m)(30.5m)
Show all financial metrics
Report incorrect company information

Protagonist Therapeutics News and Updates

Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease

NEWARK, Calif., Nov. 27, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease...

Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14

NEWARK, Calif., Nov. 7, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Stifel 2018 Healthcare Conference at 8:45 a.m. EST at the Lotte New York...

Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

NEWARK, Calif., Nov. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the third quarter ended September 30, 2018, and provided a corporate update on its clinical development programs. "We are pleased to report continued progress ...

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200

NEWARK, Calif., Nov. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced top-line results from the Phase 1 study of PTG-200, an oral peptide interleukin-23 receptor antagonist, in 80 normal healthy volunteers. Results of the randomized, double-blind,...

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300

NEWARK, Calif., Sept. 27, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective...

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1

NEWARK, Calif., Sept. 24, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at 4:40 p.m. at the...
Show more
Report incorrect company information

Protagonist Therapeutics Company Life and Culture

Report incorrect company information

Protagonist Therapeutics Frequently Asked Questions

  • When was Protagonist Therapeutics founded?

    Protagonist Therapeutics was founded in 2007.

  • Who are Protagonist Therapeutics key executives?

    Protagonist Therapeutics's key executives are Dinesh Patel, David Y. Liu and Mark Smythe.

  • How many employees does Protagonist Therapeutics have?

    Protagonist Therapeutics has 49 employees.

  • Who are Protagonist Therapeutics competitors?

    Competitors of Protagonist Therapeutics include PHEMI Health Systems, Wellcentive and Pacific Biosciences of California.

  • Where is Protagonist Therapeutics headquarters?

    Protagonist Therapeutics headquarters is located at 100 521 Cottonwood Dr, Milpitas.

  • Where are Protagonist Therapeutics offices?

    Protagonist Therapeutics has an office in Milpitas.

  • How many offices does Protagonist Therapeutics have?

    Protagonist Therapeutics has 1 office.